At September 30, 2025, Edesa had cash and cash equivalents of $10.8 million and working capital of $10.4 million. Subsequent to the fiscal year end, the company received $3.4 million in net proceeds, ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...

A 2025 report from a bipartisan, congressionally chartered commission warns that China is closing in on a win, and the United ...

Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech ...

A raging bull market for biotech stocks and a good story have transformed an ineffective weight loss drug into a Wall Street ...

In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

Commentary: Biotechnology lets scientists engineer natural ingredients into products, often more sustainably than if they were farmed. Here's what to know. Deenie is a CNET Perspectives contributor ...

In September 2024, Akeso, a little-known Chinese biopharmaceutical company, announced that clinical trials had shown that its new drug could halt the progression of a type of lung cancer for nearly a ...

Something unusual is happening to biotech stocks: They’re going up. A drug-pricing deal between Pfizer and the White House and a spate of deals have sent the SPDR S&P Biotech exchange-traded fund up 9 ...

A hand holds up a tamper-safe orange bottle filled with oblong white pills against a red-tinted background of Chinese yuan. As China’s biopharmaceutical industry churns out more innovative molecules, ...